If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVLK.L Share News (VLK)

  • There is currently no data for VLK

Small Cap round-up: Vislink, Source BioScience, Alliance Pharma..........

Wed, 24th Mar 2010 18:43
New chief executive Duncan Lewis has restructured Vislink's operations so they are based on customer sectors rather than technologies. The core news and entertainment division reported much lower revenues as its major US contract came to an end. The law enforcement division is benefiting from increased spending on surveillance equipment and the marine division is gaining work onshore. Revenues fell from £101m to £94.7m in 2009. The underlying operating profit declined by two-fifths to £5.22m and pre-tax profit slumped from £8.77m to £4.75m. The dividend is unchanged at 1.25p a share. Net cash was £611,000 at the end of 2009. Capitalised development spending increased from £2.95m to £3.2m. The order book was worth £20.3m at the end of 2009. Cost savings will help profits to recover this year. Evolution forecasts that profits will improve to £8.6m in 2010. Asia and the Middle East provide the most opportunities. Vislink is ready to make acquisitions and they are likely to be in Asia so that the company has a base in the region. Healthcare and life sciences services provider Source BioScience moved into profit in 2009. There was a swing from a loss of £300,000 to a profit of £200,000 on revenues that were 11% higher at £12.7m. All three divisions made a positive contribution in the year. Source is investing in DNA sequencing equipment and expects this to be a growth area. The outsourced pharma services operation made its first profit. Alliance Pharma reported a 44% increase in revenues to £31.2m in 2009 thanks to a combination of organic and acquisitive growth. Pre-exceptional profits jumped from £2.4m to £8.6m, although that doesn't include a £2.8m write-off mainly relating to the capitalised development costs of a drug. Alliance specialises in mature drugs and treatments which have a solid revenue base. Some of its drugs are more than 50 years old but they still have significant revenues. The recent purchase of Cambridge Laboratories for up to £16.4m has added cancer drugs to the portfolio. A much-improved second half performance helped eg solutions to return to profit in the year to January 2010. The operations management software supplier reported a 13% increase in revenues to £4.15m. A loss of £753,000 was turned into a profit of £99,000 in 2009. Higher gross margins and cost cutting were behind the improvement. More software licences were sold in the most recent period. Weak construction demand has hit trading at quantity surveyor Baqus and although work is being won it is at lower margins than in the past. The order book is flat at £8m. Management had already warned that the interim figures would be disappointing. Revenues fell from £3.98m to £3.85m in the six months to December 2009. A profit of £365,000 has turned into a loss of £470,000, including an exceptional charge for redundancies and office closures.

Related News

Alliance Pharma loss narrows in 2024 due to reduced impairment charges
8 Apr 2025

Alliance Pharma loss narrows in 2024 due to reduced impairment charges

(Alliance News) - Alliance Pharma PLC on Tuesday reported a narrowed loss for 2024 despite a decline in revenue, due to a reduction in impairment char...

Alliance Pharma confident despite softer sales
8 Apr 2025

Alliance Pharma confident despite softer sales

(Sharecast News) - Alliance Pharma posted weaker full-year revenues on Tuesday, but insisted it remained well-positioned for medium-term growth.

Alliance Pharma board backs final GBP362 million takeover bid
10 Mar 2025

Alliance Pharma board backs final GBP362 million takeover bid

(Alliance News) - Alliance Pharma PLC on Monday said it has agreed to a final increased cash offer of 64.75 pence per share from Dbay Advisors Ltd and...

VLK.L News

Order intake slows at Vislink
19 May 2010

Order intake slows at Vislink

Secure communications products and services provider Vislink said trading in the first quarter of 2010 remained mixed with underlying order intake dow...

Small Cap round-up: Vislink, Source BioScience, Alliance Pharma..........
24 Mar 2010

Small Cap round-up: Vislink, Source BioScience, Alliance Pharma..........

New chief executive Duncan Lewis has restructured Vislink's operations so they are based on customer sectors rather than technologies. The core news a...

Techmark movers: Vislink in deal with Fujitsu
3 Mar 2010

Techmark movers: Vislink in deal with Fujitsu

Vislink has entered into a global partnership with Fujitsu Frontech Media Solutions, part of the Fujitsu Group. The partnership will allow Vislink t...

TechMARK movers: Slippage hits Vislink
8 Dec 2009

TechMARK movers: Slippage hits Vislink

Broadcast technology supplier Vislink says that its full year profits for 2009 will be lower than forecast. Expected contracts have failed to come to ...

Vislink issues profit warning
8 Dec 2009

Vislink issues profit warning

Secure communications specialist Vislink said delays in customers orders means the group will not meet the levels of revenue originally anticipated fo...

Wednesday tips round-up: ARM, Reckitt Benckiser, Cineworld
28 Oct 2009

Wednesday tips round-up: ARM, Reckitt Benckiser, Cineworld

ARM Holdings cheered investors yesterday when it outstripped consensus estimates on its profits before exceptional charges at a time when the semi-con...

Vislink Q3 trading in line
27 Oct 2009

Vislink Q3 trading in line

Secure communications specialist Vislink said third quarter trading has been in line with company expectations. Underlying order intake at constant ...

TechMARK movers: Vislink's profits drop
26 Aug 2009

TechMARK movers: Vislink's profits drop

Secure communications specialist Vislink saw pre-tax profit in the first half slump to £0.48m from £2.29m. 'Customers in our News & Entertainment m...